IFNL1 and viral infectious disease: Indeed, IL‐29 seems to be a promising candidate for the treatment of acute and chronic viral infections such as hepatitis C or E.25, 26 However, based on our data, therapeutic approaches targeting IL‐29 might display reduced efficacy in neonates.